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Abstract
Purpose To determine the added value of mammography in women with focal breast complaints and the utility of initial 
targeted ultrasound in this setting.
Methods Women with symptomatic breast disease who were evaluated by breast imaging (mammography/digital breast 
tomosynthesis and ultrasound) between January 2016 and December 2016 in the Radboud University Medical Centre were 
included. We retrospectively collected the following data: date of birth, indication of imaging, visibility on mammography/
ultrasound, whether biopsy was taken, additional findings, BI-RADS-classification, pathology and follow-up results.
Results A total of 494 women were included (mean age 46.5, range 30 to 93). In 49 women (9.9%), symptomatic breast 
cancer was diagnosed, all visible during targeted ultrasound. The negative predictive value of targeted ultrasound was very 
high (99.8%). Additional findings on mammography were significantly more often malignant when the symptomatic lesion 
was also malignant (3.8% vs 70%, P < 0.05). In only one patient with symptoms caused by a benign finding, an incidental 
malignancy was detected on mammography outside the area of complaint (detection rate 2.2/1000 examinations).
Conclusions The contribution of mammography for cancer detection in women with focal breast complaints is very low when 
targeted ultrasound is performed. Additional findings are most common in patients with symptomatic breast cancer. Our 
results suggest that initial targeted ultrasound is a more appropriate initial tool for the evaluation of focal breast complaints. 
Mammography could be performed on indication only.
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Abbreviations
BI-RADS  Breast imaging reporting and data system
DCIS  Ductal carcinoma in situ
MRI  Magnetic resonance imaging
PPV  Positive predicting value
Introduction
In the Netherlands per 1000 women, 29.7 women with focal 
breast symptoms visit a general practitioner per year. The 
majority of visits is due to a palpable mass, but also skin 
changes, nipple changes, nipple excretion and focal pain are 
included. The highest incidence of focal breast complaints 
is found in women aged 25 to 44 years (48 per 1000) [1]. 
Although the exact fraction of these women that is referred 
to a breast clinic is unknown, roughly 70.000 women (1/3rd) 
with focal breast complaints present at a radiology depart-
ment in the Netherlands annually.
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For women over 30, the baseline examination includes 
mammography (and digital breast tomosynthesis in most 
hospitals) followed by targeted ultrasound at the spot of the 
focal breast complaint. Biopsy is performed when needed 
according to various national guidelines [2, 3]. The role of 
breast ultrasound has gradually increased in this evaluation 
due to advances in the technology [4] and improvement of 
interpretation of ultrasound findings by breast radiologists.
The Sydney Breast Imaging Accuracy Study suggests that 
ultrasound may be an appropriate initial imaging examina-
tion in young women (< 45 years) [5]. Lehman et al. [6] 
likewise concluded that targeted ultrasound has a high sen-
sitivity (95.7%) and high negative predictive value (NPV) 
(99.9%) in women between 30 and 39 years, and should be 
the primary imaging modality of choice. They noted that the 
added value of mammography is very low [6, 7]. In a study 
by Leung et al. [7] it was concluded that there is no added 
value for repeating mammography when a negative mam-
mography performed within 12 months is already present. 
It appears that the added value of mammography mostly lies 
in the determination of multifocality and/or the extent of 
disease in case of breast malignancy [8]. Furthermore, mam-
mography may be helpful when the radiologist is uncertain 
about the ultrasound findings or in case of a discrepancy 
between the clinical assessment and the ultrasound.
Still, these studies only focused on relatively young 
women, and do therefore not inform on the effect of age 
for supplemental cancer detection with mammography. This 
retrospective study aims to assess the diagnostic accuracy of 
targeted ultrasound and the added value of mammography 
in all women over 30 years of age presenting with a focal 
breast complaint.
Methods
We performed a retrospective cohort study to assess the 
value of mammography and targeted ultrasound in women 
presenting with focal breast complaints at our department.
Patients
We searched the Picture Archiving and Communication Sys-
tem (PACS) for all patients who underwent a mammography 
and targeted ultrasound at the same day at our department 
between the 1st of January and 31st of December 2016.
This yielded 904 patients. 410 patients were subsequently 
excluded for various reasons as listed in Fig. 1. The final 
study cohort therefore consisted of 494 women.
Imaging
All patients underwent regular bilateral mammography 
and/ or digital breast tomosynthesis consisting of a two-
view (craniocaudal and mediolateral oblique) examination 
of both breasts using a Siemens MAMMOMAT Inspira-
tion VB60 with Prime Technology (Siemens, Erlan-
gen, Germany). All mammograms were automatically 
Fig. 1  Exclusion criteria
383Breast Cancer Research and Treatment (2021) 185:381–389 
1 3
scored for breast density using Volpara software (version 
3.4.1/1.5.5.1.) (Volpara solutions, Christchurch, New 
Zealand).
All targeted ultrasound examinations were performed 
by 1 of 5 dedicated breast radiologists with 3–26 years of 
experience using a SIEMENS Healthcare Acuson S2000 
Ultrasound system with a preset mode for breast imaging.
Data extraction
For all women we obtained the radiological assessment from 
the reports, including a full lexicon description of eventual 
findings according to the Breast Imaging Reporting and 
Data System (BI-RADS) Lexicon, and a BI-RADS score 
for both mammography and targeted ultrasound [9]. In case 
of incomplete or unclear data in the report, images were 
reviewed by a breast radiologist (L.A.) with 4 years of expe-
rience, if needed another experienced breast radiologist was 
consulted to obtain consensus.
For all patients the following items were scored: indica-
tion of the examination, mammographic density, presence of 
an abnormality at the focal complaint site on mammography 
and ultrasound, type of abnormality at the focal complaint 
site for mammography and ultrasound, morphologic char-
acteristics on both imaging modalities, suspicion of malig-
nancy regarding the focal complaint site scored by BI-RADS 
classification, additional findings on imaging (mammogra-
phy and ultrasound separately), performance of biopsy for 
the focal complaint, performance of biopsy for additional 
findings, lesion histopathology.
Data was collected in Castor EDC, a cloud-based Elec-
tronic Data Capture system (Castor EDC, Amsterdam, NL).
Data interpretation and ground truth
BI-RADS 1 and 2 were considered as a negative result and 
BI-RADS 3, 4 and 5 were considered as a positive result. 
Ground truth was obtained from the histopathological 
reports when a breast biopsy was performed. A small group 
of women (n = 3) underwent magnetic resonance imaging 
(MRI) of the breasts for further analysis. For all women at 
least 2 years of negative follow-up was used to confirm the 
absence of breast cancer. Follow-up was deemed negative 
in case women didn’t come back for the same complaint, the 
lesions were downgraded after a period of follow-up (down-
graded to BI-RADS 2) and if women were referred again 
with the same focal breast complaint and still underwent 
biopsy that was negative for breast cancer. Follow-up was 
regarded positive when a woman developed breast cancer in 
the 2 years after inclusion, regardless of her previous focal 
breast complaint.
Statistics
The primary outcome of this study was the frequency of 
unexpected malignant findings diagnosed by mammography 
alone. In these women the breast complaints are explained 
by normal or benign results according to the targeted ultra-
sound, but the mammography revealed a misinterpreted 
abnormality at the focal spot of complaint or revealed an 
abnormality in a non-symptomatic area. Sensitivity, specific-
ity, negative and positive predictive value of both modalities 
combined and targeted ultrasound alone were calculated. We 
considered mammography to be beneficial in cases where it 
had a clinical consequence that was different from the rec-
ommendation of the ultrasound examination and led to the 
detection of a histopathological proven malignancy.
We compared cancer yield and frequency of false positive 
findings between imaging modalities using chi-square and 
McNemar tests. 95% confidence intervals (CI) were calcu-
lated. A p-value of < 0.05 was considered significant. The 
statistical analyses were performed in IBM SPSS Statistics 
Version 25.
Results
The median age of our population (n = 494) was 46.5 years 
(range 30.2–93.7 years) (Fig. 2).
The clinical indications for breast imaging were divided 
into five subgroups: focal lump (82.0%), focal skin or nip-
ple retraction (7.3%), hemorrhagic nipple discharge (3.2%), 
focal pain or “different feeling” (6.9%) and nipple eczema 
(0.6%).
Most of the women (80.6%, average 47.5 years) had a 
negative or benign result after imaging. According to the 
reports of mammography and ultrasound, complaints were 
caused by normal fibroglandular tissue or a benign lesion 
at the focal spot, respectively classified as BI-RADS 1 
(n = 234) and BI-RADS 2 (n = 164). 19.4% of cases was 
classified as BI-RADS 3, 4 or 5 (Fig. 3).
Combining both modalities, 260 (52.6%) women were 
diagnosed with a symptomatic lesion that correlated with 
the complaint. Targeted ultrasound showed 248 symptomatic 
abnormalities (varying from BI-RADS 2 to BI-RADS 5 
lesions) whereas only 161 symptomatic abnormalities were 
visible on mammography (Table 1). In other words, in 99 
cases (99/494: 20.0%) the (symptomatic) breast lesion was 
only visible on ultrasound and mammographically occult.
164 of the 260 visualized lesions (63.1%) were unam-
biguously benign based upon diagnostic imaging (i.e. clas-
sified as BI-RADS 2).
There were 96 examinations (96/494:19.4%) classified 
as BI-RADS 3, 4 or 5, all visible on targeted ultrasound. 
A total of 91 ultrasound guided biopsies were performed 
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Fig. 2  Age during inclusion
Fig. 3  Frequency of BI-RADS scores given in the analysis of focal breast complaints
Table 1  Imaging of focal complaint
Imaging 
complaint
Normal Abnormality Size (mm) BI-RADS 2 BI-RADS 3 BI-RADS 4 BI-RADS 5 Biopsies Malignant
MG 333 (67.4%) 161 (32.6%) 7.2 82 (50.1%) 24 (14.9%) 17 (10.6%) 38 (23.6%) 79 (49.1%) 47 (29.2%)
US 246 (49.8%) 248 (50.2%) 8.6 164 (66.1%) 36 (14.5%) 21 (8.5%) 39 (15.7%) 83 (33.5%) 49 (19.8%)
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in 86 women to evaluate abnormalities that correlated 
with the focal breast complaint(s). In five women two dif-
ferent symptomatic lesions were biopsied. The remainder 
consisted of eleven BI-RADS 3 lesions, which underwent 
short term follow-up, except for one woman. This specific 
young woman (30 years of age, presenting during lacta-
tion period) presented with a lump that was already getting 
smaller. According to the ultrasound imaging her complaint 
was probably caused by a galactocele (also getting smaller 
compared to ultrasound imaging in the previous year). She 
was recommended to return only when the mass would grow. 
There was one case which turned out to be more suspicious 
after a second ultrasound two months later, the BI-RADS 
classification was changed to BI-RADS 4a and it turned out 
to be malignant (lobular carcinoma) after biopsy and his-
topathological analysis. All other BI-RADS 3 lesions were 
subsequently downgraded to BI-RADS 1 or 2. The women 
(3) who underwent an MRI for further analysis of their 
breast complaints were eventually reassured. In one case 
non-mass enhancement with wash-out at the location of the 
complaint, MR guided biopsy was needed to exclude malig-
nancy (pathology: adenosis). The other two MRIs showed no 
enhancement at the site of the complaint and were regarded 
as conclusive.
51 of 96 examinations (53.1%) were proven to be malig-
nant (mean size: 22 mm on ultrasound, range 3 to 50). Char-
acteristics of detected cancers and biopsied benign lesions 
are presented in the Appendix Table 2.
Thirty-nine lesions were classified as BI-RADS 5, of 
which 38 turned out to be malignant (the last was a radial 
scar without signs of malignancy as proven by surgi-
cal excision) (PPV 97.4%; 38/39). Nine of 20 BI-RADS 
4 lesions turned out to be malignant (PPV 45.0%), and 2 
of 36 BI-RADS 3 lesions (PPV 5.6%) (Fig. 4). In total 49 
symptomatic breast cancers were thus found during clinical 
imaging work-up of the focal complaint, excluding addi-
tional findings and malignancies detected during follow-up.
In summary, all symptomatic malignancies were visible 
during targeted ultrasound and the radiologists classified 
all malignant lesions as BI-RADS 3 or higher (i.e. local 
sensitivity was 100%). Two cancers were occult on mam-
mography; hence, the local sensitivity of mammography was 
95.9% (47/49).
There was no significant difference in cancer detection 
between the different indications. The presence of a lump 
was the main presented complaint (82.0%; 405/494). When 
biopsies were taken there was a 54.3% chance of malignancy 
(38/70). The relative risk of having breast cancer in case of a 
lump was 9.4% (38/405). In women with “focal skin/nipple 
retraction” (36/494) all performed biopsies yielded malig-
nant results (100%; 10/10). This complaint resulted in the 
detection of malignancy in 27.8% (10/36). The relative risk 
of having breast cancer in case of “focal pain/ different feel-
ing” was 3% (1/34). In our study we did not observe breast 
cancer in the group of women with indication “hemorrhagic 
nipple discharge” (15/494) and “nipple eczema” (3/494).
Additional findings
In 294 cases (59.5%: 294/494) an additional finding was 
reported, defined as an abnormality on imaging that did 
not correlate with the focal breast complaint. 268 (90.9%: 
267/294) lesions were classified as BI-RADS 2 and usually 
reflected benign calcifications or cysts away from the area 
of the focal complaint. The remaining 35 additional find-
ings in 34 women were deemed suspicious [14 BI-RADS 
3 (4.8%; 14/295), 17 BI-RADS 4 (5.8%:17/295) and 4 
BI-RADS 5 (1.4%:4/295)]. Eleven suspicious additional 
Fig. 4  Malignancy at the focal 
complaint site, pathologically 
proven
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findings were reported in women with cancer at the focal 
complaint, whereas 25 suspicious findings were reported 
in women with benign findings at the site of complaint.
Twenty-three women underwent biopsy for an addi-
tional finding (8 with malignancy and 16 without malig-
nancy at the focal complaint site), whereas supplemental 
imaging (MRI n = 1) and follow-up (n = 10) were used 
in the other women (all without malignancy at the focal 
complaint site). In two women with an additional lesion 
(a BI-RADS 4 and a BI-RADS 5 lesion) no additional 
biopsy was performed because malignancy was detected 
at the site of the complaint, and this finding would not 
alter management. However, the finding was shown to be 
malignant at subsequent histopathological evaluation of 
the surgical specimen in one patient (with an BI-RADS 
5 lesion at the focal complaint site). The other patient 
who did not undergo additional biopsy was a 92-years old 
woman (with an BI-RADS 5 lesion at the focal complaint 
site) who didn’t undergo surgery because of the chosen 
palliative policy. All suspicious lesions that underwent 
(only) follow-up were eventually downgraded to BI-RADS 
1 or BI-RADS 2, except for one woman with additional 
suspicious calcifications who refused further analysis or 
follow-up (Fig. 5). The additional finding (indistinct mass 
on ultrasound) that was evaluated with MRI showed nor-
mal breast tissue in this specific area, no malignancy was 
found.
Twenty-four women underwent biopsy for the additional 
lesions detected on mammography (8 lesions in women with 
cancer and 17 lesions in women without cancer at the focal 
complaint site). Eighteen biopsies yielded benign results. 
One biopsy of a cluster calcifications was not representative 
but was subsequently regarded as benign (classified as BI-
RADS 2) after a follow-up period of 2 years and 9 months 
with mammography (Fig. 5).
Overall, additional findings were significantly more often 
malignant when the symptomatic lesion was also malignant 
(5/8) than when the symptomatic lesion was benign (1/17), 
p < 000.1. The negative predictive value of targeted ultra-
sound is very high (99.8%). The only woman (1/494; 0.2%) 
who was diagnosed with a malignancy while presenting with 
benign complaints, was referred for a focal skin retraction 
in her right breast, which turned out to be Mondors’ disease 
based on mammographic and targeted ultrasound evaluation. 
The mammography, however, showed a small area (6 mm) of 
clustered calcifications in the contralateral breast (left side). 
Stereotactic biopsy revealed ductal carcinoma in situ (DCIS) 
grade I–II. This detection had no clinical consequences (a 
Fig. 5  Additional findings
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wait-and-see policy was chosen), because she was already 
diagnosed with metastatic ovarian cancer. She eventually 
died within 1 year from that disease.
In women under 40 years of age (135/494) only two 
(mean age of 36.5 years) were diagnosed with breast can-
cer. Both presented with focal breast complaints at the site 
of the cancer. In this age category eight reports mentioned 
additional findings classified as BI-RADS 3 or more after 
the assessment of mammography and further analyses all 
showed benign outcome.
Follow‑up
Two patients developed breast cancer after initial benign 
findings (2/445) within 2 years from presentation. One 
65-year-old woman originally presented with a lump in her 
left breast, which was biopsied and diagnosed as benign 
intraductal papilloma. She returned to our department 
12 months later for re-evaluation because of growth of the 
lump. Repeat biopsies confirmed intraductal papilloma 
but now with the presence of a DCIS component, which 
led to subsequent surgical removal of the papilloma. The 
other patient (a 37-year-old woman) was initially diagnosed 
with a cyst (size 9 mm), explaining the focal complaints at 
9 o’clock in her left breast. She returned ten months later 
with a small lump in the same breast, although this time at 3 
o’clock. This new lump was seen as a small oval hyperdense 
mass, sharply demarcated on the mammography and in ret-
rospect unchanged compared to the mammogram (Volpara 
density score C) obtained ten months before. The ultrasound 
showed a non-cystic suspicious lesion, which was biopsied 
and yielded invasive ductal carcinoma with DCIS (size 
6 mm). Subsequent breast MRI revealed three small tumors 
in her left breast; one ductal carcinoma and two lobular car-
cinomas at histopathological analysis.
All additional findings (> BI-RADS 3) without biopsy 
were downgraded to BI-RADS 1 or 2 after follow-up.
Discussion
In this retrospective study, we demonstrated that breast radi-
ologists accurately evaluated focal breast complaints by tar-
geted ultrasound only. Although previous studies are limited 
to a certain age category, our patient population consists of 
all women over 30 years of age. All symptomatic malig-
nancies were visible during targeted ultrasound and were 
classified as “BI-RADS 3 or more” lesions. Even all lobular 
carcinomas (n = 7) were visible on targeted ultrasound in our 
study. In fact, the sensitivity of targeted ultrasound is higher 
compared to mammography in our study population. This is 
consistent with other studies [10, 11]. In total 35 additional 
suspicious findings were found by mammography alone, 
including 6 malignant lesions. Of these, one malignancy 
(DCIS) was detected on mammography while the complaint 
was explained by a benign lesion. All other additional malig-
nant lesions were found in cases with (already) symptomatic 
breast cancer.
We observed only a small difference between the final 
diagnoses causing the focal complaints by targeted ultra-
sound and mammography in terms of cancer versus non-
cancer (100 vs. 95.9%). Noteworthy is, however, that around 
35% of the symptomatic (predominantly benign) abnormali-
ties were occult on mammography. This may be explained 
by the high amount of dense breasts (70.3% breast density 
Volpara C or D) in our study population, which might be due 
to the relatively younger age of women presenting with focal 
breast complaints than is typical for screening populations.
A much bigger difference between the two modalities 
was observed in the detection of additional findings away 
from the focal complaint site. Targeted ultrasound led to 
detection of supplemental abnormalities in 28.7% (142/494) 
of cases (mainly cysts in the surrounding breast tissue), 
whereas mammography detected additional findings in 
55.5% (274/494). However, most additional findings were 
clearly benign (e.g. calcifications with a benign aspect) and 
did not change clinical management.
The perceived added value of mammography is the detec-
tion of non-symptomatic malignant lesions in women pre-
senting with focal complaints elsewhere. However, accord-
ing to our analysis the detection rate of additional cancer in 
women without cancer at the spot of the focal complaint is 
very low (1/494), even when compared to our national breast 
cancer screening program (approximately 6/1000 (National 
Evaluation team for Breast Cancer screening, 2014)). This 
might be caused by the fact that the women presenting with 
focal breast complaints were on average younger (mean 
48.9 years of age) than women in the screening population 
(50–75 years of age), which reduces both the frequency of 
breast cancer and the sensitivity of mammography. Moreover, 
our lower rate of additional cancer than expected, could be 
due to the relatively high participation in the National screen-
ing program, which can lead to a slight selection bias with 
regard to the group of women who are eligible for screening.. 
About one third of the study population (167 women) would 
be eligible for screening according to the national guidelines 
(women aged ≥ 50 and ≤ 75). We do not know exactly which 
women participated in the screening program. However, our 
low detection rate of additional cancer equals the results of 
a study in Ireland [12]. They reported detection of 2,1 per 
1000 additional cancers, although their study was limited to 
a younger age category (35–39).
In women with breast cancer at the spot of the focal com-
plaint, mammography detected additional malignant lesions 
(multifocal disease) in a fair number of patients (5/8; 62.5%). 
Mammography in this setting should therefore be regarded 
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as a staging examination that may better show the extent of 
disease than targeted ultrasound, and may show contralat-
eral breast cancer in women at increased risk. Hence, there 
is obvious value in the performance of mammography in 
women with focal complaints diagnosed as cancer. However, 
other studies have shown that for staging purposes, mam-
mography may not be the best tool, and for example breast 
MRI has a much better concordance with histopathological 
examination [13].
The performance of mammography in women with focal 
abnormalities does lead to a substantial number of false posi-
tive findings. In our study 28 women (28/445; 6.3%) under-
went further analyses because of the detection of an additional 
finding on mammogram, with afterwards benign outcome 
(such as complex cyst, pseudoangiomatous stromal hyper-
plasia, intraductal papilloma, fibroadenoma and adenosis). 
Logically, the biopsy rate increases with age with regard to 
the additional findings. The biopsy rate for additional find-
ings in our study population with a benign outcome of the 
complaint is higher than to the biopsy rate of the Ireland study 
(3.8% vs. 2.8%) [12], likely due to the higher average age in 
our population. Apart from the (in retrospective unnecessary) 
benign biopsies, the extra follow-ups (in BI-RADS 3 cases) 
will presumably also cause a psychological impact [14].
Based on these findings, it appears that mammog-
raphy in the setting of focal breast complaints must be 
regarded as a screening examination with a very low yield 
(1/494 = 0.002%) and a relatively high false positive rate 
(28/445 = 0.06%) in women with benign outcome with 
regard to the focal complaint, that compares poorly to 
national screening programs.
There are several limitations of our retrospective study. 
The reports of mammography and ultrasound were in prac-
tice sometimes combined and the ultrasound findings were 
interpreted at the time of already known outcome of the 
mammography. In some cases it wasn’t always “easy” to 
identify the symptomatic lesion (if there were more lesions) 
on mammography because there was no marker used which 
correlated to the complaint. Another limitation is the lack 
of subgroup analyses because of the small sample size. 
Furthermore, the follow-up period was not very long (only 
24 months after inclusion).
Our findings suggest that in women with focal breast 
complaints it might be better to use mammography on indi-
cation than as standard initial evaluation technique. The 
decision whether mammography is required could be made 
after interpretation of the targeted ultrasound due to the high 
negative predictive value of this examination. This is in line 
with other studies [15–17]. Such an approach will prevent 
the performance of mammography in case of clearly benign 
outcomes according to the targeted ultrasound (BI-RADS 
1 or 2), also improving the cost-effectiveness of the breast 
imaging clinic.
Conclusion
Breast radiologists are well capable to distinguish “typical” 
benign lesions from malignant lesions using targeted ultra-
sound alone in women with focal breast complaints. The 
added value of mammography in patients with focal breast 
complaint is generally very low. Further, prospective evalu-
ation of our findings is, however, required.
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Total biopsied lesions 86 24
Biopsied benign 38 18




 Cyst (complex)/hyperplasia 5 6




Biopsied malignant 48 1
 Intraductal papilloma with DCIS 1 –
 DCIS – 1
 IDC (with DCIS) 40 –
 ILC (with DCIS) 7 –
 Other – –
